3087 The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC)

F.Mueller; K.Jordan; P.Jahn; T.Behlendorf; C.Sippel; T.Kegel; H.H.Wolf; H.J.Schmoll

首页> 外文期刊>European Journal of Cancer Supplements >3087 The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC)

【24h】

3087 The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC)

机译：3087 NK-1拮抗剂阿瑞匹坦（APR）与Granisetron和地塞米松联合用于高剂量化疗（HDC）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
F.Mueller; K.Jordan; P.Jahn; T.Behlendorf; C.Sippel; T.Kegel; H.H.Wolf; H.J.Schmoll;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. [J] . Jordan K, Jahn F, Jahn P, Bone marrow transplantation . 2011,第6期

机译：大剂量化疗（大剂量美法仑和大剂量T-ICE：紫杉醇，异环磷酰胺，卡铂，依托泊苷）中的NK-1受体拮抗药：三联止吐组合的疗效和安全性。
2. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study [J] . AlbanyC., BramesM.J., FauselC., Journal of Clinical Oncology . 2012,第32期

机译：接受5天顺铂联合化疗方案的生殖细胞肿瘤患者中口服神经激肽1拮抗剂aprepitant联合5HT3受体拮抗剂和地塞米松的随机，双盲，安慰剂对照III期交叉研究肿瘤小组研究
3. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study [J] . AlbanyC., BramesM.J., FauselC., Journal of Clinical Oncology . 2012,第32期

机译：接受5天顺铂联合化疗方案的生殖细胞肿瘤患者中口服神经激肽1拮抗剂aprepitant联合5HT3受体拮抗剂和地塞米松的随机，双盲，安慰剂对照III期交叉研究肿瘤小组研究
4. A SINGLE-CENTER EXPERIENCE USING CHEMOTHERAPY WITH MELPHALAN-DEXAMETHASONE (M-DEX) IN PATIENTS WITH AL AMYLOIDOSIS AND ADVANCED ORGAN INVOLVEMENT NOT ELIGIBLE FOR HIGH-DOSE MELPHALAN THERAPY (HDM) [C] . U. Hegenbart, T. Bochtler, J.B. Dengler, International Symposium on Amyloidosis . 2008

机译：使用化学疗法的单中心经验与Melphalan-Dexamethasone（M-DEX）的Al淀粉样蛋白病和先进器官参与没有资格获得高剂量Melphalan治疗（HDM）
5. A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin [O] . Hironobu Ohmatsu, Kenji Eguchi, Tetsu Shinkai, 1994

机译：大剂量甲氧氯普胺联合地塞米松与格拉尼司琼联合地塞米松在接受大剂量顺铂化疗的患者中的随机交叉研究
6. Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients [O] . L. Zhang, S. Lu, A. Dechaphunkul, 2017

机译：单剂量NEPA的疗效结果，Netupitant和Palonosetron的固定组合，与用于预防中国患者的化疗诱导的化疗诱导的恶心和呕吐（CINV）的3天的3天
7. Mutagenic Effectiveness of Known Doses of gamma Radiation in Combination with Weightlessness on Habrobracon Quarterly Progress Report, 1 Apr. - 30 Jun. 1967 [R] . Von Borstel, R. C. 1968

机译：已知剂量的γ辐射与失重相结合对Habrobracon季度进展报告，1967年4月1日至1967年6月30日的致突变效应

3087 The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC)

著录项

相似文献

相关主题

期刊订阅